Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer/Eyetech Macugen To Launch In First Quarter With "Unambiguous" Label

This article was originally published in The Pink Sheet Daily

Executive Summary

The ophthalmic agent clears FDA under priority review procedures; "It is for all neovascular" age-related macular degeneration, Eyetech COO says. Company expects Macugen will receive broad coverage under Medicare Part B.

You may also be interested in...



GSK Drawn To Archemix’s Table By Aptamers For (Another) Option Deal

Package of seven potential anti-inflammatory drugs includes interleukin-23 inhibitor program.

GSK Drawn To Archemix’s Table By Aptamers For (Another) Option Deal

Package of seven potential anti-inflammatory drugs includes interleukin-23 inhibitor program.

Genentech’s Lucentis Ships June 30 Following Approval

Ranibizumab, for the treatment of wet age-related macular degeneration, will be priced at a substantial premium to Pfizer/OSI's Macugen.

Related Content

Topics

UsernamePublicRestriction

Register

PS058444

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel